Loading...
•
Jun 30, 2023
Nektar Q2 2023 Earnings Report
Reported financial results for the second quarter ended June 30, 2023.
Key Takeaways
Nektar Therapeutics reported a revenue of $20.5 million and a net loss of $51.1 million, or $0.27 loss per share, for the second quarter of 2023. The company's cash and investments in marketable securities were $409.4 million as of June 30, 2023, which are expected to support operations into at least the middle of 2026.
Cash and investments in marketable securities were $409.4 million as of June 30, 2023.
Nektar expects cash and marketable securities to support operations into at least the middle of 2026.
A Phase 2b study of rezpegaldesleukin in patients with atopic dermatitis is planned, with initial data expected in the first half of 2025.
Nektar is working to advance next pipeline candidates in immunology with an IND filing in 2024 and continuing Phase 2 studies of NKTR-255 in liquid and solid tumors.
Forward Guidance
Nektar looks forward to initiating a Phase 2b study of rezpegaldesleukin, advancing pipeline candidates in immunology with an IND filing in 2024, and continuing Phase 2 studies of NKTR-255 while evaluating strategic partnership pathways.
Positive Outlook
- Initiating a Phase 2b study of rezpegaldesleukin in patients with atopic dermatitis.
- Achieving objective to have initial data from the rezpegaldesleukin study in the first half of 2025.
- Advancing next pipeline candidates in immunology with an IND filing in 2024.
- Continuing Phase 2 studies of NKTR-255 in liquid and solid tumors.
- Evaluating strategic partnership pathways.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...